clinical trial · NCT06934044
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Multiple MyelomaCevostamabTocilizumab
brief summary
This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
started
May 13, 2025
primary completion
Nov 15, 2028
completion
Nov 15, 2028
last updated
Aug 6, 2026
official title
A Phase Ib, Open-Label, Single-Arm, Multicenter Trial Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Patients With Relapsed or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol